For many patients, the binary choice between total abstinence and continued drinking is a clinical dead end. A new London-based healthtech startup, Nul, is building a subscription service for the space in between, combining a decades-old pharmacological protocol with modern telehealth delivery [Tech.eu, Feb 2026]. Founded in 2024, the company recently secured a $1 million seed round led by dmg ventures and BYVP to launch its medication-led program in the UK and begin preparations for a US entry [The Tech Founders, Feb 2026].
The Wedge of Non-Abstinence
Nul’s core bet is that a significant population seeks to reduce, but not necessarily eliminate, their alcohol consumption. The clinical wedge is the Sinclair Method (TSM), a protocol using opioid antagonists like naltrexone or nalmefene taken before drinking to block the endorphin reward and gradually weaken cravings [choosenul.com/support, 2026]. While the method has been studied for decades, Nul aims to make it accessible through a remote, integrated service. Patients get virtual consultations and prescriptions through a partner, Blueco Healthcare, which is registered with the UK's Care Quality Commission. Medication is delivered to the home, and the subscription includes digital coaching and optional at-home liver function tests via a partnership with Thriva [Vestbee, Feb 2026]. The model explicitly avoids the rehab or inpatient setting, targeting individuals who may be deterred by the stigma or logistical hurdles of traditional treatment.
Navigating a Clinical and Commercial Path
The funding from dmg ventures, the venture arm of Daily Mail and General Trust, signals a belief in the consumer subscription potential of this clinical approach. The capital is earmarked for team expansion and customer acquisition in the UK [HT World, Feb 2026]. For a solo-founded company like Nul, led by Matus Maar, the immediate path involves proving both clinical efficacy in a real-world setting and commercial traction. The public record does not yet detail patient volumes or clinical outcomes data, which will be critical for building trust with both users and a broader medical community. The company’s partnerships with regulated clinical and testing services provide a necessary scaffold, but the long-term motion will depend on demonstrating improved patient outcomes at scale.
- Clinical validation. While Nul cites a 78% reduction or elimination rate from Sinclair Method studies, real-world adherence and outcomes in a remote, subscription-based model remain to be published [choosenul.com/programmes, 2026].
- Market education. The concept of “controlled drinking” or “harm reduction” as a valid treatment goal still faces skepticism in some circles, requiring clear patient communication.
- Execution scale. As a solo founder venture, Nul must rapidly build out operational, clinical, and growth teams to manage the complexities of medication supply, patient safety, and subscription retention.
The company is entering a sensitive clinical arena. Alcohol use disorder affects millions, and the standard of care today often still prioritizes abstinence-based programs, which can leave patients who are not ready for that commitment without structured support. Nul’s bet is that by marrying a specific pharmacological protocol with the convenience of telehealth, it can reach that underserved patient population. The next twelve months will be about translating seed capital into tangible patient numbers and beginning to gather the outcome data that could make its case, not just to investors, but to the wider world of addiction medicine.
Sources
- [Tech.eu, Feb 2026] UK healthtech startup Nul raises $1M to support alcohol reduction efforts | https://tech.eu/2026/02/16/uk-healthtech-startup-nul-raises-1m-to-support-alcohol-reduction-efforts/
- [The Tech Founders, Feb 2026] HealthTech Startup Nul Raises $1M in Seed Funding to Modernise Alcohol Reduction | https://thetechfounders.co.uk/news/uk-healthtech-startup-nul-raises-1m-in-seed-funding/
- [Vestbee, Feb 2026] Nul secures $1M | https://vestbee.com/insights/articles/nul-secures-1-m
- [HT World, Feb 2026] Alcohol reduction platform Nul raises $1m seed funding | https://www.htworld.co.uk/news/digital-health/alcohol-reduction-platform-nul-raises-1m-seed-funding-digi26/
- [choosenul.com, 2026] Support | https://www.choosenul.com/support
- [choosenul.com, 2026] New Programmes | https://www.choosenul.com/programmes